Autres langues Alzinova AB

Actions

ALZ

SE0007413455

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Stockholm 18:00:00 10/09/2026			Varia. 5j.	Varia. 1 janv.
0,9370 ^SEK	+3,31%		+10,24%	+13,03%

20/08	Alzinova AB (publ) publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
20/08	RX Securities réitère son conseil d'achat sur Alzinova avec une valeur théorique de 3,50 couronnes	FW

Autres langues

10/09	The Board of Directors of Alzinova resolves on a rights issue of units of approximately SEK 51 million
10/09	Alzinova initiates operational start-up of global Phase 2 study with ALZ-101
24/08	Alzinova: Diagnostics readout next, partner process delayed – Q2 review
20/08	Alzinova (Q2 Review): Capitalizing on diagnostics opportunities
20/08	Alzinova AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
20/08	Alzinova publishes interim report for the period January - June 2026
07/07	BioVal™ analysis of Alzinova's ALZ-101 – rNPV of SEK 7.1B
24/06	Alzinova: Newsflow update – diagnostic optionality and TO4 proceeds
24/06	Alzinova AB and Fujirebio Enter Letter of Intent for Potential Commercialization of Blood-Based Alzheimer?S Diagnostic Test
24/06	Alzinova Inks Nonbinding Deal with Fujirebio for Potential Alzheimer's Blood-based Diagnostic Test
24/06	Alzinova signs Letter of Intent with Fujirebio regarding potential commercialization of blood-based Alzheimer’s diagnostic test
12/06	Warrants of series TO4 were exercised to approximately 94.2 percent and the Company will receive approximately 15.3 million
08/06	Alzinova announces preliminary outcome of the exercise of warrants of series TO4
03/06	The last day of trading with the warrants of series TO4 in Alzinova is today, June 3, 2026
26/05	Bulletin from the Annual General Meeting of Alzinova AB (publ)
25/05	The subscription price for warrants of series TO4 in Alzinova has been determined to SEK 0.32 and the exercise period begins today
21/05	Alzinova has received subscription commitments and underwriting commitments corresponding to 80 percent of the exercise of warrants of series TO4
20/05	Alzinova’s clinical results with ALZ-101 now published in Alzheimer’s Research & Therapy
20/05	Alzinova AB Publishes Clinical Results with ALZ-101 in Alzheimer?s Research & Therapy
13/05	Alzinova (Q1 Review): Scientific validation and strategic optionality
13/05	Alzinova AB Reports Earnings Results for the First Quarter Ended March 31, 2026
13/05	Alzinova Q1 loss after financial items SEK 6 mln
13/05	Alzinova publishes interim report for the period January – March 2026
12/05	Interview with Dr. Marwan Sabbagh – why ALZ-101 represents a next-generation approach in Alzheimer’s Disease
11/05	Alzinova’s clinical results with ALZ-101 to be published in scientific journal